ALKS
Price
$29.49
Change
-$0.26 (-0.87%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
4.55B
27 days until earnings call
COLL
Price
$33.30
Change
-$0.16 (-0.48%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
1.24B
34 days until earnings call
Ad is loading...

ALKS vs COLL

Header iconALKS vs COLL Comparison
Open Charts ALKS vs COLLBanner chart's image
Alkermes
Price$29.49
Change-$0.26 (-0.87%)
Volume$17.56K
Capitalization4.55B
Collegium Pharmaceutical
Price$33.30
Change-$0.16 (-0.48%)
Volume$3.44K
Capitalization1.24B
ALKS vs COLL Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. COLL commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and COLL is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (ALKS: $29.75 vs. COLL: $33.46)
Brand notoriety: ALKS and COLL are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 146% vs. COLL: 93%
Market capitalization -- ALKS: $4.55B vs. COLL: $1.24B
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. COLL’s [@Pharmaceuticals: Other] market capitalization is $1.24B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green whileCOLL’s FA Score has 2 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • COLL’s FA Score: 2 green, 3 red.
According to our system of comparison, ALKS is a better buy in the long-term than COLL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while COLL’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 4 bearish.
  • COLL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than COLL.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а +4.68% price change this week, while COLL (@Pharmaceuticals: Other) price change was +0.36% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.37%. For the same industry, the average monthly price growth was +2.59%, and the average quarterly price growth was -9.58%.

Reported Earning Dates

ALKS is expected to report earnings on Apr 23, 2025.

COLL is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.37% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than COLL($1.24B). COLL has higher P/E ratio than ALKS: COLL (30.17) vs ALKS (8.90). COLL YTD gains are higher at: 16.789 vs. ALKS (3.442). ALKS has higher annual earnings (EBITDA): 519M vs. COLL (308M). ALKS has more cash in the bank: 773M vs. COLL (311M). ALKS has less debt than COLL: ALKS (372M) vs COLL (674M). ALKS has higher revenues than COLL: ALKS (1.66B) vs COLL (567M).
ALKSCOLLALKS / COLL
Capitalization4.55B1.24B367%
EBITDA519M308M169%
Gain YTD3.44216.78921%
P/E Ratio8.9030.1730%
Revenue1.66B567M293%
Total Cash773M311M249%
Total Debt372M674M55%
FUNDAMENTALS RATINGS
ALKS vs COLL: Fundamental Ratings
ALKS
COLL
OUTLOOK RATING
1..100
6376
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
3131
SMR RATING
1..100
3923
PRICE GROWTH RATING
1..100
5054
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (70) in the Pharmaceuticals Other industry is in the same range as ALKS (94) in the Biotechnology industry. This means that COLL’s stock grew similarly to ALKS’s over the last 12 months.

COLL's Profit vs Risk Rating (31) in the Pharmaceuticals Other industry is in the same range as ALKS (31) in the Biotechnology industry. This means that COLL’s stock grew similarly to ALKS’s over the last 12 months.

COLL's SMR Rating (23) in the Pharmaceuticals Other industry is in the same range as ALKS (39) in the Biotechnology industry. This means that COLL’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Price Growth Rating (50) in the Biotechnology industry is in the same range as COLL (54) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew similarly to COLL’s over the last 12 months.

ALKS's P/E Growth Rating (92) in the Biotechnology industry is in the same range as COLL (100) in the Pharmaceuticals Other industry. This means that ALKS’s stock grew similarly to COLL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSCOLL
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
76%
Momentum
ODDS (%)
N/A
Bullish Trend 4 days ago
72%
MACD
ODDS (%)
N/A
Bullish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
67%
Bullish Trend 4 days ago
75%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 10 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
62%
Bearish Trend 19 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bearish Trend 4 days ago
73%
Aroon
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
82%
View a ticker or compare two or three
Ad is loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with VTRS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+2.41%
VTRS - ALKS
34%
Loosely correlated
-0.44%
COLL - ALKS
28%
Poorly correlated
+1.52%
PAHC - ALKS
26%
Poorly correlated
+0.34%
AMPH - ALKS
26%
Poorly correlated
-1.60%
ESPR - ALKS
25%
Poorly correlated
+2.26%
More

COLL and

Correlation & Price change

A.I.dvisor tells us that COLL and ALKS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that COLL and ALKS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
+1.52%
ALKS - COLL
28%
Poorly correlated
+2.41%
SUPN - COLL
27%
Poorly correlated
-1.15%
ASRT - COLL
27%
Poorly correlated
-2.60%
DVAX - COLL
23%
Poorly correlated
-0.72%
AMPH - COLL
23%
Poorly correlated
-1.60%
More